234 related articles for article (PubMed ID: 18791716)
1. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
Dumitru CD; Antonysamy MA; Gorski KS; Johnson DD; Reddy LG; Lutterman JL; Piri MM; Proksch J; McGurran SM; Egging EA; Cochran FR; Lipson KE; Tomai MA; Gullikson GW
Cancer Immunol Immunother; 2009 Apr; 58(4):575-87. PubMed ID: 18791716
[TBL] [Abstract][Full Text] [Related]
2. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
Gorski KS; Waller EL; Bjornton-Severson J; Hanten JA; Riter CL; Kieper WC; Gorden KB; Miller JS; Vasilakos JP; Tomai MA; Alkan SS
Int Immunol; 2006 Jul; 18(7):1115-26. PubMed ID: 16728430
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
4. IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma.
Jiang Q; Wei H; Tian Z
J Immunother; 2008; 31(6):555-62. PubMed ID: 18528299
[TBL] [Abstract][Full Text] [Related]
5. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells.
Smits EL; Cools N; Lion E; Van Camp K; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Cancer Immunol Immunother; 2010 Jan; 59(1):35-46. PubMed ID: 19449004
[TBL] [Abstract][Full Text] [Related]
6. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
Hammerbeck DM; Burleson GR; Schuller CJ; Vasilakos JP; Tomai M; Egging E; Cochran FR; Woulfe S; Miller RL
Antiviral Res; 2007 Jan; 73(1):1-11. PubMed ID: 16959331
[TBL] [Abstract][Full Text] [Related]
7. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA.
Berger M; Ablasser A; Kim S; Bekeredjian-Ding I; Giese T; Endres S; Hornung V; Hartmann G
J Immunother; 2009 Apr; 32(3):262-71. PubMed ID: 19242374
[TBL] [Abstract][Full Text] [Related]
8. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells.
Akazawa T; Ebihara T; Okuno M; Okuda Y; Shingai M; Tsujimura K; Takahashi T; Ikawa M; Okabe M; Inoue N; Okamoto-Tanaka M; Ishizaki H; Miyoshi J; Matsumoto M; Seya T
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):252-7. PubMed ID: 17190817
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.
Dumitru CD; Antonysamy MA; Tomai MA; Lipson KE
Cancer Biol Ther; 2010 Jul; 10(2):155-65. PubMed ID: 20519933
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
11. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
Paget C; Mallevaey T; Speak AO; Torres D; Fontaine J; Sheehan KC; Capron M; Ryffel B; Faveeuw C; Leite de Moraes M; Platt F; Trottein F
Immunity; 2007 Oct; 27(4):597-609. PubMed ID: 17950005
[TBL] [Abstract][Full Text] [Related]
12. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7.
Bourquin C; Schmidt L; Lanz AL; Storch B; Wurzenberger C; Anz D; Sandholzer N; Mocikat R; Berger M; Poeck H; Hartmann G; Hornung V; Endres S
J Immunol; 2009 Nov; 183(10):6078-86. PubMed ID: 19890064
[TBL] [Abstract][Full Text] [Related]
13. Essential role of Toll-like receptors for dendritic cell and NK1.1(+) cell-dependent activation of type 1 immunity by Lactobacillus pentosus strain S-PT84.
Koizumi S; Wakita D; Sato T; Mitamura R; Izumo T; Shibata H; Kiso Y; Chamoto K; Togashi Y; Kitamura H; Nishimura T
Immunol Lett; 2008 Oct; 120(1-2):14-9. PubMed ID: 18620001
[TBL] [Abstract][Full Text] [Related]
14. NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo.
Grundy MA; Zhang T; Sentman CL
Cancer Immunol Immunother; 2007 Aug; 56(8):1153-61. PubMed ID: 17160409
[TBL] [Abstract][Full Text] [Related]
15. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect.
Penafuerte C; Galipeau J
Cancer Immunol Immunother; 2008 Aug; 57(8):1197-206. PubMed ID: 18214474
[TBL] [Abstract][Full Text] [Related]
16. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.
Nishio S; Yamada N; Ohyama H; Yamanegi K; Nakasho K; Hata M; Nakamura Y; Fukunaga S; Futani H; Yoshiya S; Ueda H; Taniguchi M; Okamura H; Terada N
Cancer Sci; 2008 Jan; 99(1):113-20. PubMed ID: 17949451
[TBL] [Abstract][Full Text] [Related]
17. [Direct and indirect antitumor effect of murine recombinant interferons].
Sakurai M; Iigo M; Sasaki Y; Hoshi A; Saijo N
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):889-95. PubMed ID: 3105463
[TBL] [Abstract][Full Text] [Related]
18. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of NK cell function against head and neck cancer in response to ss-isRNA requires TLR7.
Pries R; Wulff S; Kesselring R; Börngen K; Xie L; Wollenberg B
Int J Oncol; 2008 Nov; 33(5):993-1000. PubMed ID: 18949362
[TBL] [Abstract][Full Text] [Related]
20. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
